Skip to main content

ORIGINAL RESEARCH article

Front. Public Health
Sec. Health Economics
Volume 12 - 2024 | doi: 10.3389/fpubh.2024.1432947
This article is part of the Research Topic World Health Day 2024: Frontiers in Public Health presents: "My Health, My Right" View all 8 articles

Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis

Provisionally accepted
Zhaoyan Chen Zhaoyan Chen *Fangyuan Tian Fangyuan Tian
  • West China Hospital, Sichuan University, Chengdu, China

The final, formatted version of the article will be published soon.

    Thank you for your letter and for the reviewers' comments concerning our manuscript entitled "Modified gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis" (ID: 1432947). Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied comments carefully and have made correction which we hope meet with approval.Revised portion are marked in red in the paper. The main corrections in the paper and the responds to the reviewer's comments are as following:1. The conclusion should be presented concisely.Response：Thank you very much for your suggestion. We have already streamlined and revised the results section of the article.2. The writing of this manuscript is not acceptable now and should be carefully revised by an English negative speaker.Response ： Thank you for your suggestion. We have thoroughly reviewed the entire document and invited native English speakers to make revisions.3. More latest reference should be included.Response：Thank you for your suggestion. We have added the latest references.

    Keywords: Gallbladder cancer (GBC), gemcitabine, oxaliplatin, Fluorouracil, Cost Effectiveness

    Received: 15 May 2024; Accepted: 02 Dec 2024.

    Copyright: © 2024 Chen and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Zhaoyan Chen, West China Hospital, Sichuan University, Chengdu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.